These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 15868116)

  • 1. Vascular protection in diabetes: a pharmacological view of angiotensin II type 1 receptor blockers.
    Kintscher U; Unger T
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S26-32. PubMed ID: 15868116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Telmisartan protects against diabetic vascular complications in a mouse model of obesity and type 2 diabetes, partially through peroxisome proliferator activated receptor-γ-dependent activity.
    Toyama K; Nakamura T; Kataoka K; Yasuda O; Fukuda M; Tokutomi Y; Dong YF; Ogawa H; Kim-Mitsuyama S
    Biochem Biophys Res Commun; 2011 Jul; 410(3):508-13. PubMed ID: 21679694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New treatment strategies for patients with hypertension and insulin resistance.
    Kurtz TW
    Am J Med; 2006 May; 119(5 Suppl 1):S24-30. PubMed ID: 16563944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telmisartan: just an antihypertensive agent? A literature review.
    Destro M; Cagnoni F; Dognini GP; Galimberti V; Taietti C; Cavalleri C; Galli E
    Expert Opin Pharmacother; 2011 Dec; 12(17):2719-35. PubMed ID: 22077832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of insulin-sensitizing property of telmisartan, a commercially available angiotensin II type 1 receptor blocker in preventing the development of atrial fibrillation.
    Yamagishi S; Takenaka K; Inoue H
    Med Hypotheses; 2006; 66(1):118-20. PubMed ID: 16154710
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct properties of telmisartan on agonistic activities for peroxisome proliferator-activated receptor γ among clinically used angiotensin II receptor blockers: drug-target interaction analyses.
    Kakuta H; Kurosaki E; Niimi T; Gato K; Kawasaki Y; Suwa A; Honbou K; Yamaguchi T; Okumura H; Sanagi M; Tomura Y; Orita M; Yonemoto T; Masuzaki H
    J Pharmacol Exp Ther; 2014 Apr; 349(1):10-20. PubMed ID: 24424487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of cardiovascular cell proliferation by angiotensin receptor blockers: are all molecules the same?
    Benson SC; Iguchi R; Ho CI; Yamamoto K; Kurtz TW
    J Hypertens; 2008 May; 26(5):973-80. PubMed ID: 18398340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating the metabolic syndrome: telmisartan as a peroxisome proliferator-activated receptor-gamma activator.
    Kurtz TW
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S9-16. PubMed ID: 15868121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PPARgamma-activating angiotensin type-1 receptor blockers induce adiponectin.
    Clasen R; Schupp M; Foryst-Ludwig A; Sprang C; Clemenz M; Krikov M; Thöne-Reineke C; Unger T; Kintscher U
    Hypertension; 2005 Jul; 46(1):137-43. PubMed ID: 15939809
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of telmisartan on insulin resistance in Japanese type 2 diabetic patients.
    Watanabe M; Inukai K; Sumita T; Ikebukuro K; Ito D; Kurihara S; Ono H; Awata T; Katayama S
    Intern Med; 2010; 49(17):1843-7. PubMed ID: 20823643
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Beyond the classic angiotensin-receptor-blocker profile.
    Kurtz TW
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S19-26. PubMed ID: 18580862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for double renin-angiotensin-aldosterone system blockade.
    Unger T; Stoppelhaar M
    Am J Cardiol; 2007 Aug; 100(3A):25J-31J. PubMed ID: 17666194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [PPARgamma-activating properties of angiotensin receptor blockers].
    Ando H; Fujimura A
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():498-501. PubMed ID: 16895217
    [No Abstract]   [Full Text] [Related]  

  • 16. Telmisartan improves insulin sensitivity in nondiabetic patients with essential hypertension.
    Benndorf RA; Rudolph T; Appel D; Schwedhelm E; Maas R; Schulze F; Silberhorn E; Böger RH
    Metabolism; 2006 Sep; 55(9):1159-64. PubMed ID: 16919533
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peroxisome proliferator-activated receptor-γ activation with angiotensin II type 1 receptor blockade is pivotal for the prevention of blood-brain barrier impairment and cognitive decline in type 2 diabetic mice.
    Min LJ; Mogi M; Shudou M; Jing F; Tsukuda K; Ohshima K; Iwanami J; Horiuchi M
    Hypertension; 2012 May; 59(5):1079-88. PubMed ID: 22454480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations of insulin resistance and the serum adiponectin level in patients with type 2 diabetes mellitus under the usual antihypertensive dosage of telmisartan treatment.
    Fuke Y; Fujita T; Satomura A; Wada Y; Matsumoto K
    Diabetes Technol Ther; 2010 May; 12(5):393-8. PubMed ID: 20388049
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effects of telmisartan and amlodipine on metabolic parameters and blood pressure in type 2 diabetic, hypertensive patients.
    Negro R; Hassan H
    J Renin Angiotensin Aldosterone Syst; 2006 Dec; 7(4):243-6. PubMed ID: 17318795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Telmisartan increases localization of glucose transporter 4 to the plasma membrane and increases glucose uptake via peroxisome proliferator-activated receptor γ in 3T3-L1 adipocytes.
    Furukawa H; Mawatari K; Koyama K; Yasui S; Morizumi R; Shimohata T; Harada N; Takahashi A; Nakaya Y
    Eur J Pharmacol; 2011 Jun; 660(2-3):485-91. PubMed ID: 21514293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.